HHTM

Dr. Harvey Dillon’s career in audiology spans more than four decades of research, innovation, and leadership that have helped shape modern hearing care around the world. A former Director of the National Acoustic Laboratories and Professor of Audiology at both Macquarie University and the University of Manchester, Dr. Dillon’s work bridges psychoacoustics, engineering, and clinical practice, influencing everything from hearing

MILAN, ITALY — Amplifon, parent company of Miracle-Ear and a global leader in hearing care services, today announced the appointment of Dr. Nicholas Reed to the newly created role of Vice President of Audiology Innovation and Research. In this role, Dr. Reed will oversee Amplifon’s research initiatives and support the company’s broader efforts in audiology and hearing health. He joins

Samsung has introduced a new app called Hearapy that it says may help reduce motion sickness by delivering a precisely timed 100 Hz tone through its Galaxy Buds4 Pro earbuds. The launch appears to translate recent academic research into a consumer-facing tool. According to Samsung, users listen to a low-frequency sine tone for 60 seconds before travel, with the sound

The NAL-NL3 fitting algorithm is now entering clinical practice, following GN’s recent global rollout—marking a significant evolution from the widely used NL2 standard. In this discussion, Pádraig Kitterick of the National Acoustic Laboratories explains how NL3 moves beyond a “one-size-fits-all” approach, introducing new modules designed for real-world listening challenges, including speech in noise and individuals with minimal or no measurable

AMSTERDAM, THE NETHERLANDS — Norgine B.V. announced that Swissmedic has granted marketing authorization for PEDMARQSI® (sodium thiosulfate solution for infusion) for the prevention of cisplatin-induced ototoxicity (hearing loss) in patients aged 1 month to <18 years with localized, non-metastatic solid tumors. The approval provides an authorized treatment option in an area of significant unmet medical need for children receiving cisplatin chemotherapy.

NEW YORK — Cearvol has announced the launch of Wave, a hearing solution designed to improve clarity, connectivity, and ease of use for people with hearing loss. Wave combines AI-based sound processing with a touchscreen charging case, aiming to deliver both performance and usability in everyday environments. The company says the system is designed to reduce complexity while supporting real-world

Hearing loss affects millions of people across all ages—but you wouldn’t know it from mainstream media. New data from a multi-country survey reveals just how rarely hearing aids and cochlear implants are seen in everyday media—and how often those portrayals miss the mark. Andrew Bellavia speaks with Ceri Whittaker, Senior External Relations Manager at GN, who leads communications around initiatives

EDEN PRAIRIE, MINNESOTA — Starkey has received two 2026 BIG AI Excellence Awards from the Business Intelligence Group. The company’s Omega AI hearing technology was recognized for its application of artificial intelligence in hearing care, while Achin Bhowmik, Ph.D., Starkey’s Chief Technology Officer and Executive Vice President of Engineering, received an individual AI Excellence Award for his leadership in AI-driven

STÄFA, SWITZERLAND – Phonak announced that its Virto R Infinio and Infinio Ultra Sphere hearing aids have been named winners in the 2026 Artificial Intelligence Excellence Awards, presented by the Business Intelligence Group. The annual awards program recognizes organizations, products, and technologies applying artificial intelligence to drive measurable impact across industries. Both devices were recognized in the health category for

MONTPELLIER, FRANCE — Sensorion on Monday reported updated six-month efficacy data from Cohort 2 of its Phase 1/2 Audiogene trial evaluating SENS-501, while also providing a development update on its GJB2 gene therapy program, GJB2-GT (SENS-601). The company said the six-month follow-up data from Cohort 2 showed sustained early efficacy signals in two of three patients treated with the higher